Rockwell Medical Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rockwell Medical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Rockwell Medical stock.
View analyst ratings for Rockwell Medical or view top-rated stocks.

1 brokerages have issued 12-month price objectives for Rockwell Medical's stock. Their RMTI stock forecasts range from $33.00 to $33.00. On average, they anticipate Rockwell Medical's stock price to reach $33.00 in the next year. This suggests a possible upside of 2,114.8% from the stock's current price.
View analysts' price targets for Rockwell Medical or view top-rated stocks among Wall Street analysts.

Rockwell Medical's stock was trading at $4.51 at the beginning of the year. Since then, RMTI shares have decreased by 67.0% and is now trading at $1.49.
View the best growth stocks for 2022 here.

Rockwell Medical saw a drop in short interest in May. As of May 31st, there was short interest totaling 242,400 shares, a drop of 40.6% from the May 15th total of 408,100 shares. Based on an average daily volume of 62,200 shares, the short-interest ratio is currently 3.9 days. Approximately 3.1% of the shares of the stock are sold short.
View Rockwell Medical's Short Interest.

Rockwell Medical is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Rockwell Medical.

Rockwell Medical, Inc. (NASDAQ:RMTI) announced its quarterly earnings results on Thursday, May, 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.15. The firm had revenue of $16.12 million for the quarter, compared to the consensus estimate of $18.80 million. Rockwell Medical had a negative trailing twelve-month return on equity of 474.88% and a negative net margin of 51.27%. During the same quarter in the previous year, the business earned ($0.08) earnings per share.
View Rockwell Medical's earnings history.

Rockwell Medical's stock reverse split on Friday, May 13th 2022. The 1-11 reverse split was announced on Friday, May 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 13th 2022. An investor that had 100 shares of Rockwell Medical stock prior to the reverse split would have 9 shares after the split.

6 employees have rated Rockwell Medical CEO Robert L. Chioini on Glassdoor.com. Robert L. Chioini has an approval rating of 22% among Rockwell Medical's employees. This puts Robert L. Chioini in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Rockwell Medical include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), IDEXX Laboratories (IDXX), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX).
View all of RMTI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rockwell Medical investors own include Immunomedics (IMMU), JinkoSolar (JKS), Seagen (SGEN), Geron (GERN), OPKO Health (OPK), Amarin (AMRN), Gilead Sciences (GILD), ImmunoGen (IMGN), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

Rockwell Medical trades on the NASDAQ under the ticker symbol "RMTI."

Rockwell Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Richmond Brothers Inc. (7.34%), Perkins Capital Management Inc. (4.39%), Vanguard Group Inc. (3.14%), Verdence Capital Advisors LLC (0.57%), Renaissance Technologies LLC (0.30%) and Northern Trust Corp (0.17%). Company insiders that own Rockwell Medical stock include Angus W Smith, David S Richmond, Russell H Ellison and Stuart M Paul.
View institutional ownership trends for Rockwell Medical.

RMTI stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Richmond Brothers Inc., and Northern Trust Corp.
View insider buying and selling activity for Rockwell Medical or view top insider-selling stocks.

RMTI stock was purchased by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Verdence Capital Advisors LLC, Renaissance Technologies LLC, and Group One Trading L.P..
View insider buying and selling activity for Rockwell Medical or or view top insider-buying stocks.

Shares of RMTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RMTI stock can currently be purchased for approximately $1.49.

Rockwell Medical (NASDAQ:RMTI) has a market capitalization of $12.73 million and generates $61.93 million in revenue each year.

Rockwell Medical employs 300 workers across the globe.

Rockwell Medical was founded in 1995.

Rockwell Medical's mailing address is 411 HACKENSACK AVENUE SUITE 501, HACKENSACK NJ, 07601. The official website for Rockwell Medical is www.rockwellmed.com. The company can be reached via phone at (248) 960-9009, via email at [email protected], or via fax at 248-960-9119.